This 2021 Topps Series 1 70 Years of Baseball Deivi Garcia Gold Autograph card features a manufacturer-obtained signature, serial numbered to just 25 copies.
2021 • Topps • Series 1 • 70 Years of Baseball Autographs • Gold
Major League Baseball • New York Yankees
New
Shipping Calculated at Checkout
30-day ReturnsNo condition-by-condition breakdown has been recorded for this card yet.
The 2021 Topps Series 1 70 Years of Baseball Autographs subset honors the sport's rich history while highlighting emerging talent like Deivi Garcia. This card, identified by the catalog number 70YA-DGA, captures the young Yankees prospect during a pivotal moment in his early career. The Gold variation distinguishes itself within the set through its premium metallic finish, offering a visually striking alternative to the standard base cards. Collectors often seek this parallel for its aesthetic appeal and the exclusivity it provides to those building specialized collections. A key feature of this release is the autograph itself. Obtained directly from the manufacturer, the signature adds a layer of authenticity and personal connection that resonates with fans of Deivi Garcia. The Gold parallel is particularly notable for its limited distribution, with a print run strictly serial numbered to 25. This scarcity makes it a highly coveted item for investors and set builders alike, who recognize the value in owning a piece of baseball history that is both rare and significant. The combination of the prestigious 70 Years of Baseball branding, the Gold treatment, and the limited serial number creates a compelling profile for any serious sports card portfolio. It stands as a testament to the enduring appeal of Topps products and the excitement surrounding young athletes making their mark in the major leagues.
11 hours ago
We'll pre-fill the product details from this catalog entry, so your listing lands on this exact page. Just add photos of your copy, pick its condition, and set your price.
The catalog profile below summarizes the card identity, featured subject, and notable collectible traits.
The core identity of the card within the set.
The subject, team, league, and sport context tied to this card.
Production details and format-specific attributes.
Material
Card Stock
Language
English
Notable collectible traits associated with this card profile.
Compare prices, grades, photos, and shipping from approved sellers.
See how many public collections currently include this card.
0 collectors have this card
Deivi Garcia's 2021 Topps Series 1 card occupies a modest tier within the broader Yankees prospect card market, reflecting his status as a highly touted arm who has yet to fully deliver on early expectations. With only one active listing currently available, the card's market is extremely thin, which can create artificial price distortions in either direction. Graded copies of this card command a measurable premium over raw examples, though overall demand remains subdued compared to higher-profile Yankees prospects from the same era.
This card features serial-numbered and autographed variants, which significantly stratify the population across different tiers of scarcity. Autographed serial-numbered parallels represent the top of the rarity hierarchy for this issue, with low-population graded copies in top grades being particularly difficult to source. The base version from Series 1 carries a standard print run typical of flagship Topps, meaning raw copies are widely available and graded base examples hold limited scarcity-driven value.
Garcia's professional trajectory has been inconsistent, with roster volatility and performance struggles tempering the early hype that surrounded his MLB debut, which keeps speculative interest relatively low. The autographed serial-numbered variants retain the strongest long-term positioning, as any resurgence in performance or a trade to a higher-profile market could trigger renewed collector interest. Grading submission trends for this card appear light, meaning a breakout moment could shift population dynamics quickly, though current market momentum suggests patient accumulation rather than aggressive pursuit.
